logo-loader
Polarean Imaging PLC

Total Voting Rights

/**/ link{ color: blue }visited{ color: #954F72 } .bj{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.bj{}p.cn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.co{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}span.cj{color:black}p.cq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.y{}span.cr{font-family:"Cambria Math","serif"}p.cs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify} table.ct{width:459.9pt;margin-left:-10.8pt;border-collapse:collapse}td.cd{width:229.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.cu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.cv{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}td.by{width:209.25pt;padding:0cm 5.4pt 0cm 5.4pt}p.cw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: right}span.cc{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}span.cx{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ca{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}td.bx{width:319.7pt;padding:0cm 5.4pt 0cm 5.4pt} p.cy{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.cz{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}td.bv{width:112.5pt;padding:0cm 5.4pt 0cm 5.4pt}p.da{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: right}span.db{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-div: italic}span.bu{font-family: "Calibri","sans-serif";color:black}p.dc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; margin: 0cm; margin-bottom: .0001pt; text-align: right}span.bt{font-family:"Calibri","sans-serif";color:black}p.dd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: right}span.de{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} span.df{font-family:"Calibri","sans-serif";color:black}td.bq{width:163.8pt;padding:0cm 5.4pt 0cm 5.4pt}td.bp{width:265.95pt;padding:0cm 5.4pt 0cm 5.4pt}td.bo{width:200.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.dg{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}td.bn{width:237.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.bm{padding:0cm 0cm 0cm 0cm}span.bl{font-size:10.0pt}p.dh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify} /**/
RNS Number : 4628X
Polarean Imaging PLC
30 April 2019
 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Total Voting Rights

 

Polarean Imaging plc (AIM: POLX), the medicalimaging technology company, with a proprietary drugdevice combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 101,435,933 ordinary shares of £0.00037 each.

 

The total issued share capital of the Company consists of 101,435,933 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

Enquiries:

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Richard Morgan, Chairman

 

 

 

 

 

 

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

 

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

 

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TVREAKLNAFLNEFF

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago

RNS

Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago